Elutia Inc (ELUT) Actualités

Elutia Announces Second Quarter 2024 Results

SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

SILVER SPRING, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”...

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in...

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”...

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Elutia Announces $13.26 Million Registered Direct Offering

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”...

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities